Please login to the form below

Not currently logged in
Email:
Password:

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Novartis gained 177Lu-PSMA-617 as part of its $2.1bn acquisition of Endocyte, which had a focus on radiopharmaceutical drugs for cancer, in October 2018. ... At the time, Novartis said radiopharma was a “key growth driver” for its business and that

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the tumour through a tumour‐targeted ligand.

  • Charting a course for expansion Charting a course for expansion

    and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics